In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

This content is currently on FREE ACCESS, enjoy another 104 days of free consultation


Incremental value of on-site computed tomography-derived fractional flow reserve for the diagnosis and management strategy of obstructive coronary artery disease in the randomized CRESCENT trials

Session Poster Session 7

Speaker Fay Nous

Congress : ESC Congress 2019

  • Topic : imaging
  • Sub-topic : CT-derived FFR
  • Session type : Poster Session
  • FP Number : P6170

Authors : F Nous (Rotterdam,NL), R Budde (Rotterdam,NL), M Lubbers (Rotterdam,NL), Y Yamasaki (Fukuoka,JP), P Musters (Rotterdam,NL), T Bruning (Rotterdam,NL), J Akkerhuis (Rotterdam,NL), M Kofflard (Dordrecht,NL), B Kietselaer (Maastricht,NL), T Galema (Rotterdam,NL), K Nieman (Palo Alto,US)

F Nous1 , R Budde1 , M Lubbers1 , Y Yamasaki2 , P Musters1 , T Bruning3 , J Akkerhuis4 , M Kofflard5 , B Kietselaer6 , T Galema1 , K Nieman7 , 1Erasmus University Medical Centre - Rotterdam - Netherlands (The) , 2Kyushu University - Fukuoka - Japan , 3Maasstad Ziekenhuis - Rotterdam - Netherlands (The) , 4Sint Franciscus Gasthuis - Rotterdam - Netherlands (The) , 5Albert Schweitzer Hospital - Dordrecht - Netherlands (The) , 6Maastricht University Medical Centre (MUMC) - Maastricht - Netherlands (The) , 7Stanford University - Palo Alto - United States of America ,


Background: Coronary computed tomography angiography (CCTA) accurately rules out coronary artery disease (CAD), but has a limited ability to predict hemodynamically significant CAD. Implementing on-site computed tomography-derived fractional flow reserve (CT-FFR) could improve the clinical value and efficiency of cardiac CT in the diagnostic work-up of patients with stable angina.

Purpose: To determine the impact of on-site CT-FFR on diagnostic effectiveness, management strategy and downstream invasive coronary angiography (ICA) in patients with suspected CAD.

Methods: 196 patients (59.1 ± 9.6 years, 47% women) with suspected CAD underwent a CCTA in the CRESCENT I and II trials. On-site CT-FFR analysis was performed in all patients with at least one =50% stenosis on CCTA (N=53). We assessed the effect of adding CT-FFR analysis to CCTA in terms of 1) diagnostic effectiveness, i.e. the number of additional tests required to determine the final diagnosis; 2) reclassification of the initial management strategy; 3) ICA efficiency, i.e. ICA rate without =50% CAD.

Results: CT-FFR was calculated in 42/53 (79%) of the eligible patients as it could not be calculated in patients with suspected coronary total occlusion (N=7), severe coronary calcification (N=2), severe CT artefacts (N=1) or missing CT images (N=1). CT-FFR =0.80 was present in 27/196 (14%) patients, including 8/196 (4%) patients with high-risk ischemia (CT-FFR =0.80 in all three vessels, left main or proximal left anterior descending coronary artery). The final diagnosis was achieved with CT-FFR in an additional 30/196 (15%) patients compared to CT alone (p<0.0001), and rendered 42/56 (75%) of additional tests unnecessary (p<0.0001). The initial management strategy was reclassified in 30/196 patients (15%, p<0.0001); 24/196 (12%) patients were reclassified to optimal medical therapy and 6/196 (3%) patients were reclassified directly to ICA including 4/8 (50%) patients with high-risk CAD on ICA. CT-FFR would result in 6/32 (19%, p=0.012) ICA cancellations in which none of the patients had high-risk CAD. The rate of ICA without =50% stenosis would decrease from 22% (7/32) to 11% (3/27) (p=0.012).

Conclusion: Implementation of CT-FFR has the potential for improved diagnostic effectiveness. Functional reclassification of CAD provides more efficient ICA referral in patients with suspected CAD compared to CTA alone.

This content is currently on FREE ACCESS, enjoy another 104 days of free consultation


Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are